口服马替洛尔或普萘洛尔治疗婴幼儿血管瘤403例临床分析

Sanamed Pub Date : 2023-01-01 DOI:10.5937/sanamed0-46005
Özlem Terzi, Esra Arslantaş, Nur Baş, Ayşe Kaçar, Pasli Uysalol, Avni Solgun, Duygu Yıldırgan, Özkan Karagenç, Ertürk Saide, Ali Ayçiçek
{"title":"口服马替洛尔或普萘洛尔治疗婴幼儿血管瘤403例临床分析","authors":"Özlem Terzi, Esra Arslantaş, Nur Baş, Ayşe Kaçar, Pasli Uysalol, Avni Solgun, Duygu Yıldırgan, Özkan Karagenç, Ertürk Saide, Ali Ayçiçek","doi":"10.5937/sanamed0-46005","DOIUrl":null,"url":null,"abstract":"Objective: Infantile hemangiomas (IH) are the most common benign vascular tumors of infancy. Propranolol (P), a nonselective beta-blocker, has been successfully used in managing IHs. Ongoing studies investigate the efficacy of the topical b-antagonist timolol maleate (TM) in IHs. The aim of this study is to assess the effects of interventions for managing infantile hemangiomas in children. Material and Methods: We retrospectively reviewed a total of 403 IH patients from March 2021 to March 2022. The patients were stratified into three groups. Patients in Group 1 were given TM at a dose of one drop topically twice a day, 0.5%. Patients in Group 2 were given P at a dose of 1 mg/kg twice a day. The patients in Group 3 did not receive any treatment, and observation was conducted solely by contacting the controls. Results: The median age of diagnosis was 5 months (range 0-60), with 57.1% of the cases being male. While TM treatment was applied to 32% of the children and P treatment was applied to 46.9% of the children, no treatment was administered in 21.1%. The most common location of hemangiomas was the face, accounting for 39.2%. Hemangiomas were observed in more than one location in 48 (12%) children. The median follow-up period for the patients was 4 months (range 0-28). Hemangiomas remained unchanged in 28.3% of all cases, shrank in 60.3%, and continued to grow in 11.4%. The primary indication for initiating TM was superficial hemangiomas and infants younger than 6 months. The leading reason for starting P significantly higher than in the other groups (p : 0.001). No statistically significant differences were observed between the groups regarding bleeding and ulceration rates (p > 0.05). Conclusion: The efficacy of propranolol in treating IH was higher than that of TM.","PeriodicalId":53269,"journal":{"name":"Sanamed","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oral topical timolol maleat or oral propranolol treatment for infantile hemangiomas: Clinical analysis of 403 patients\",\"authors\":\"Özlem Terzi, Esra Arslantaş, Nur Baş, Ayşe Kaçar, Pasli Uysalol, Avni Solgun, Duygu Yıldırgan, Özkan Karagenç, Ertürk Saide, Ali Ayçiçek\",\"doi\":\"10.5937/sanamed0-46005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Infantile hemangiomas (IH) are the most common benign vascular tumors of infancy. Propranolol (P), a nonselective beta-blocker, has been successfully used in managing IHs. Ongoing studies investigate the efficacy of the topical b-antagonist timolol maleate (TM) in IHs. The aim of this study is to assess the effects of interventions for managing infantile hemangiomas in children. Material and Methods: We retrospectively reviewed a total of 403 IH patients from March 2021 to March 2022. The patients were stratified into three groups. Patients in Group 1 were given TM at a dose of one drop topically twice a day, 0.5%. Patients in Group 2 were given P at a dose of 1 mg/kg twice a day. The patients in Group 3 did not receive any treatment, and observation was conducted solely by contacting the controls. Results: The median age of diagnosis was 5 months (range 0-60), with 57.1% of the cases being male. While TM treatment was applied to 32% of the children and P treatment was applied to 46.9% of the children, no treatment was administered in 21.1%. The most common location of hemangiomas was the face, accounting for 39.2%. Hemangiomas were observed in more than one location in 48 (12%) children. The median follow-up period for the patients was 4 months (range 0-28). Hemangiomas remained unchanged in 28.3% of all cases, shrank in 60.3%, and continued to grow in 11.4%. The primary indication for initiating TM was superficial hemangiomas and infants younger than 6 months. The leading reason for starting P significantly higher than in the other groups (p : 0.001). No statistically significant differences were observed between the groups regarding bleeding and ulceration rates (p > 0.05). Conclusion: The efficacy of propranolol in treating IH was higher than that of TM.\",\"PeriodicalId\":53269,\"journal\":{\"name\":\"Sanamed\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sanamed\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5937/sanamed0-46005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sanamed","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/sanamed0-46005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:婴幼儿血管瘤是婴幼儿最常见的良性血管瘤。普萘洛尔(P)是一种非选择性β受体阻滞剂,已成功用于治疗IHs。正在进行的研究调查了局部b-拮抗剂马来酸替马洛尔(TM)在IHs中的疗效。本研究的目的是评估干预措施对儿童血管瘤的治疗效果。材料和方法:我们回顾性分析了2021年3月至2022年3月期间共403例IH患者。将患者分为三组。第一组患者给予TM,剂量为1滴,局部注射,每日2次,0.5%。2组患者给予P,剂量为1 mg/kg,每日2次。第3组患者未接受任何治疗,仅与对照组联系进行观察。结果:中位诊断年龄为5个月(范围0 ~ 60岁),男性占57.1%。32%的患儿接受TM治疗,46.9%的患儿接受P治疗,21.1%的患儿不接受治疗。血管瘤最常见的部位为面部,占39.2%。48例(12%)儿童出现多处血管瘤。患者的中位随访期为4个月(范围0-28)。28.3%的病例血管瘤保持不变,60.3%的病例血管瘤缩小,11.4%的病例血管瘤继续增长。启动TM的主要适应症是浅表血管瘤和小于6个月的婴儿。开始的主要原因P显著高于其他组(P: 0.001)。两组间出血和溃疡发生率无统计学差异(p >0.05)。结论:心得安治疗IH的疗效优于中药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Oral topical timolol maleat or oral propranolol treatment for infantile hemangiomas: Clinical analysis of 403 patients
Objective: Infantile hemangiomas (IH) are the most common benign vascular tumors of infancy. Propranolol (P), a nonselective beta-blocker, has been successfully used in managing IHs. Ongoing studies investigate the efficacy of the topical b-antagonist timolol maleate (TM) in IHs. The aim of this study is to assess the effects of interventions for managing infantile hemangiomas in children. Material and Methods: We retrospectively reviewed a total of 403 IH patients from March 2021 to March 2022. The patients were stratified into three groups. Patients in Group 1 were given TM at a dose of one drop topically twice a day, 0.5%. Patients in Group 2 were given P at a dose of 1 mg/kg twice a day. The patients in Group 3 did not receive any treatment, and observation was conducted solely by contacting the controls. Results: The median age of diagnosis was 5 months (range 0-60), with 57.1% of the cases being male. While TM treatment was applied to 32% of the children and P treatment was applied to 46.9% of the children, no treatment was administered in 21.1%. The most common location of hemangiomas was the face, accounting for 39.2%. Hemangiomas were observed in more than one location in 48 (12%) children. The median follow-up period for the patients was 4 months (range 0-28). Hemangiomas remained unchanged in 28.3% of all cases, shrank in 60.3%, and continued to grow in 11.4%. The primary indication for initiating TM was superficial hemangiomas and infants younger than 6 months. The leading reason for starting P significantly higher than in the other groups (p : 0.001). No statistically significant differences were observed between the groups regarding bleeding and ulceration rates (p > 0.05). Conclusion: The efficacy of propranolol in treating IH was higher than that of TM.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
23
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信